

Dimitris Stellas

Associate Researcher

Institute of Chemical Biology

Phone: +30.210. 7273830

Fax: +30.210.7273831

E-mail: dstellas@eie.gr

Website: www.eie.gr

Professional Appointments (Academia – Industry)

Current position: **Researcher/Group leader**
National Hellenic Research Foundation

Previous

appointments:

2022: **Research Fellow**

National Cancer Institute (NCI), vaccine branch, human retrovirus section at National Institutes of Health (NIH) USA.

2017: **Postdoctoral Researcher**

Laboratory of Cancer Biology, Biomedical Research Foundation of the Academy of Athens, (BRFAA)

2010: **Military Service/ Specialized Researcher**

Pathology department in the 401 General Military Hospital

2009: **Research Assistant/ Postdoctoral Researcher**

Laboratory of Chemical Carcinogenesis and Genetic Toxicology, Institute of Biological Research & Biotechnology, National Hellenic Research Foundation (NHRF)

2008: **Research Assistant**

Laboratory of Cellular and Molecular Oncology, Biochemistry Department, Hellenic Pasteur Institute (HPI)

Academic Achievements

2010: **PhD in Medicine. Classification: 10/10 (magna cum laude)**

Department of Biological Chemistry, Athens Medical School, Greece

PhD thesis: Study of heat shock protein 90 (HSP90) on cancer development, Supervisor: Dr. A.G.Papavasileiou. The main work was performed under the supervision of Dr. E. Patsavoudi in the Lab of

2003: Molecular and Cellular Oncology of the Hellenic Pasteur Institute.
B.Sc in Biology, Dept of Biology, University of Patras, Greece
BSc dissertation: Cloning of the human gene of bone morphogenetic protein 2 (BMP2) into pcDNA3 vector and stable transfecting it into C2C12 human cell line.
Supervisor: Professor A. G. Papavasileiou
 Laboratory of Biochemistry, Patras Medical School, Greece

Awards

Participation in Awarded presentations:

1. Fellows Award for Research Excellence 2021 (FARE) NIH/NCI: Eradication of Triple Negative Breast Cancer (TNBC) murine tumors after hetIL-15 monotherapy correlates with a novel population of intratumoral dendritic cells, in addition to increased infiltration of T, NK and cDC1 cells. Dimitris Stellas.
2. Milstein Abstract Award for Cytokines 2020 Virtual Meeting. hetIL-15 monotherapy increases intratumoral CD8⁺ T cytotoxic cells and reverses the metabolic dysfunction in murine breast tumors. Sevasti Karaliota, Dimitris Stellas, Vasiliki Stravokefalou, Bethany Nagy, Cristina Bergamaschi, Barbara K. Felber and George N. Pavlakis.
3. May 2015: 10th European Workshop in Drug Design, Siena, Italy. Best Poster presentation, poster title: “Structure- and ligand-based drug design studies for identification of novel Myc inhibitors”. Maria-Elena Liosi, Dimitris Stellas, Argiris Efstratiadis, Zoe Cournia
4. 2011 Paxinos Award from Hellenic society for Neuroscience: PROX1 suppresses the proliferation of neuroblastoma cells via action in p27-KIP1 and CDC25A. Iosifina-Petrina Foskolou, Dimitris Stellas, Ismini Rozani and Panagiotis Politis.
5. 2007: Best oral presentation award in the 3d Hellenic Anti carcinogenic Congress. Athens 26-29 April 2007. Monoclonal antibody 4C5 immunostains human melanomas and inhibits melanoma cell invasion and metastasis. Dimitris Stellas and Evangelia Patsavoudi.

Patents

D. Stellas, Z. Cournia, C. Tamvakopoulos, A. Klinakis & A. Efstratiadis
 Novel Compounds for use in treating or preventing cancerous diseases European Patent Application number EP 15 175 918.0

Funding

- 1.NIH NCI/RFA, Co-administration of heterodimeric IL-15, anti-mesothelin antibodies and immunotoxins for treatment of Pancreatic Ductal Adenocarcinoma, 2019 (Co- PI)
- 2.NIH NCI/RFA, Study of hetIL-15 effects on pancreatic ductal adenocarcinoma using KPC GEM mice, 2017 (Co- PI)
- 3.Euronanomed 2 Grant, Self-assembling dendrimer based nanotheranostics to combat cancer, 2016 (Co-PI)
- 4.Hellenic Company of Metastatic Liver Disease Grant, Patient derived xenografts for evaluation of novel drugs for pancreatic ductal adenocarcinoma, 2016 (D.Stellas PI)
- 5.BioRad Grant, Evaluation of a novel platform for long non-coding RNAs derived from tissues of patients baring pancreatic ductal adenocarcinoma, 2016 (D.Stellas PI)

Membership

Editorial board member for Nanomaterials

Editorial board member for *Journal of Molecular Biochemistry*

Editorial board member for CPQ Cancer

Member of the American Association of Cancer Research (AACR)

Member of the American Society of Clinical Oncology (ASCO)

Member of the Society for Immunotherapy and Cancer (SITC)

Member of the Hellenic Union of Biochemical Researchers (HSBMB)

Invited Speaker

1. Invited speaker in panhellenic congress: Molecular Medicine from the laboratory to clinical practice. 30 June -2 July 2022.
2. Invited oral presentation in the 20th European congress of internal medicine: “SARS-CoV-2 antibody kinetics eight months from COVID-19 onset: Persistence of spike antibodies but loss of neutralizing antibodies in 24% of convalescent plasma donors”. 2022
3. Invited speaker in the 21st Center of Cancer Research (CCR) FYI colloquium 2021. From mechanisms to therapies: current highlights in cancer research.
4. Invited speaker in the 2020 American Association of Cancer Research (AACR) annual meeting. (Virtual meeting II June 22-24, 2020).
5. Invited speaker in the 21st Clinical Oncology congress in Hilton hotel Athens Greece, ‘Therapeutic effects of an anti-Myc drug on mouse pancreatic cancer.’ 2015
6. Invited speaker in Beth Israel Deaconess Medical Center, Harvard Medical School by Dr. Kotaridis, ‘Modeling PIK3CA Oncogenic Mutations in Breast and

Colon Cancers for the development of targeted Anticancer Drugs and Diagnostics', 2014

7. Invited speaker in Mayo Clinic Rochester Minnesota by Dr. Van Deursen in the Kogold center of aging. 'Analysis of the S-phase arrest in mitotic instability', 2012
8. Invited for training in Columbia University New York by Dr. Szabolcs on pathology of pancreas, 2012
9. Invited speaker: CANGENIN - High-throughput screens in genome integrity and cancer. Oxford May 24-28, 2010

Mentoring & Teaching Activities

100mentors partner: <https://www.100mentors.com/mentors>

Thesis Committees & Supervision of Junior Researchers

1. 2022-present: Supervision of Master's thesis of Ms Christina Papanikolaou, 'DNA damage response network in response to treatment with nivolumab in Head and Neck Squamous Cell Carcinoma Patients.
2. 2017-2022: Supervision of Ph.D. thesis of Vasiliki Stravokefalou entitled 'The role of cellular immunity in the treatment of pancreatic cancer'
3. 2015-2017: Supervision of Msc thesis of Ourania Fari, (entitled 'The involvement of c-MYC oncoprotein in immunological aspects of pancreatic cancer progression in mouse models')(Co- supervision with NKUOA)
4. Supervision of Msc thesis of Vassiliki Stravokefalou, entitled 'Study of the role of PIK3Ca gain of function mutations in Breast Cancer chemo-resistance, in vitro and in vivo. (Co- supervision with NKUOA)
5. 2013-2014: Supervision of Msc thesis of Lambrini Tsoutsi, entitled: 'The role of Igf1 and Igf2 in the development of mouse embryos.' (Co- supervision with NKUOA)
6. Participation in the supervision of master 'rotation' students in BRFAA.
7. 2004-2009: Invited speaker for the postgraduate and PhD-candidate lectures series of the Cellular Oncology and Biochemistry Laboratory, of the Hellenic Pasteur Institute.
8. 2004-2009: Participation in the supervision of diploma theses of undergraduate and PhD students, Cellular Oncology and Biochemistry Laboratory, Hellenic Pasteur Institute.
9. 2004-2005: Research Assistant, Dept. of Medical Instruments Technology, Technological Educational Institute of Athens. Participation of the reformation of Under Graduates' Schedule. Aiming the upgrade of an in vitro laboratory and in the same time to maintain its educational role.

Peer-reviewed Research Publication List

1. Stefanou D, Kouvela M, **Stellas D**, Voutetakis K, Papadodima O, Syrigos K and Souliotis VL. Article Oxidative Stress and Deregulated DNA Damage Response Network in Lung Cancer Patients. *Biomedicines* 2022, 10, 1248. doi.org/10.3390/biomedicines10061248
2. Eptaminitaki GC, Wolff N, **Stellas D**, Sifakis K, Baritaki S. Long Non-Coding RNAs (lncRNAs) in Response and Resistance to Cancer Immunosurveillance and Immunotherapy. *Cells*. 2021 Nov 26;10(12):3313. doi: 10.3390/cells10123313.
3. Thomopoulos TP, Rosati M, Terpos E, **Stellas D**, Hu X, Karaliota S, Bouchla A, Katagas I, Antoniadou A, Mentis A, Papageorgiou SG, Politou M, Bear J, Donohue D, Kotanidou A, Kalomenidis I, Korompoki E, Burns R, Pagoni M, Grouzi E, Labropoulou S, Stamoulis K, Bamias A, Tsiodras S, Dimopoulos MA, Pavlakis GN, Pappa V, Felber BK. Kinetics of Nucleocapsid, Spike and Neutralizing Antibodies, and Viral Load in Patients with Severe COVID-19 Treated with Convalescent Plasma. *Viruses*. 2021 Sep 15;13(9):1844. doi:10.3390/v13091844.PMID: 34578426
4. Gkikas D, **Stellas D**, Polissidis A, Manolakou T, Kokotou MG, Kokotos G, Politis PK. Nuclear receptor NR5A2 negatively regulates cell proliferation and tumor growth in nervous system malignancies. *Proc Natl Acad Sci USA*. 2021 Sep 28;118(39):e2015243118. doi: 10.1073/pnas.2015243118.PMID: 34561301
5. Bergamaschi, C., Terpos, E., Rosati, M., Angel, M., Bear, J., **Stellas, D.**, Karaliota, S., Apostolakou, F., Bagratuni, T., Patseas, D., Gumeni, S., Trougakos, I.P., Dimopoulos, M.A., Felber, B.K., and Pavlakis, G.N.: Systemic IL-15, IFN- γ , and IP-10/CXCL10 signature associated with effective immune response to SARS-CoV-2 in BNT162b2 mRNA vaccine recipients. *Cell Rep*. 36: 109504, 2021.
6. Control of SARS-CoV-2 infection after Spike DNA or Spike DNA+Protein co-immunization in rhesus macaques. Rosati M., Agarwal M., Hu X., Devasundaram S., **Stellas D.**, Chowdhury B., Bear J., Burns R., Donohue D., Pessaint L., Andersen H., Terpos E., Dimopoulos M.A, Wlodawer A., Mullins I., Venzon D.J, Pavlakis G.N, Felber B.K *Plos Pathogens* doi: /10.1101/2021.06.11.448032
7. Terpos E, **Stellas D**, Rosati M, Sergentanis TN, Hu X, Politou M, Pappa V, Ntanasis-Stathopoulos I, Karaliota S, Bear J, Donohue D, Pagoni M, Grouzi E, Korompoki E, Pavlakis GN, Felber BK, Dimopoulos MA. SARS-CoV-2 antibody kinetics eight months from COVID-19 onset: Persistence of spike antibodies but loss of neutralizing antibodies in 24% of convalescent plasma donors. *Eur J Intern Med*. 2021 May 18:S0953-6205(21)00161-8. doi: 10.1016/j.ejim.2021.05.010.
8. Pappa V, Bouchla A, Terpos E, Thomopoulos TP, Rosati M, **Stellas D**, Antoniadou A, Mentis A, Papageorgiou SG, Politou M, Kotanidou A, Kalomenidis I, Poulakou G, Jahaj E, Korompoki E, Grigoropoulou S, Hu X, Bear J, Karaliota S, Burns R, Pagoni M, Trontzas I, Grouzi E, Labropoulou S, Stamoulis K, Bamias A, Tsiodras S, Felber BK, Pavlakis GN, Dimopoulos MA. A Phase II Study on the Use of Convalescent Plasma for the Treatment of Severe COVID-19- A Propensity Score-Matched Control Analysis. *Microorganisms*. 2021 Apr 11;9(4):806. doi: 10.3390/microorganisms9040806. PMID: 33920489
9. Bergamaschi C, Stravokefalou V, **Stellas D**, Karaliota S, Felber BK, Pavlakis GN. Heterodimeric IL-15 in Cancer Immunotherapy. *Cancers (Basel)*. 2021 Feb 17;13(4):837. doi: 10.3390/cancers13040837.PMID: 33671252
10. Papadopoulos A, Chalmantzi V, Hyvönen M, **Stellas D**, Syrrou M, Fotsis T, Murphy C. Supporting data on combined transcriptomic and phosphoproteomic analysis of

- BMP4 signaling in human embryonic stem cells. *Data Brief*. 2021 Feb 6;35:106844. doi: 10.1016/j.dib.2021.106844. eCollection 2021 Apr. PMID: 33644271
11. Papadopoulos A, Chalmantzi V, Mikhaylichenko O, Hyvönen M, **Stellas D**, Kanhere A, Heath J, Cunningham DL, Fotsis T, Murphy C. Combined transcriptomic and phosphoproteomic analysis of BMP4 signaling in human embryonic stem cells. *Stem Cell Res*. 2020 Dec 18;50:102133. doi: 10.1016/j.scr.2020.102133. Online ahead of print. PMID: 33383406
 12. Terpos E, Politou M, Sergeantanis TN, Mentis A, Rosati M, **Stellas D**, Bear J, Hu X, Felber BK, Pappa V, Pagoni M, Grouzi E, Labropoulou S, Charitaki I, Ntanasis-Stathopoulos I, Moschandreou D, Bouhla A, Saridakis S, Korompoki E, Giatra C, Bagratuni T, Pefanis A, Papageorgiou S, Spyridonidis A, Antoniadou A, Kotanidou A, Syrigos K, Stamoulis K, Panayiotakopoulos G, Tsiodras S, Alexopoulos L, Dimopoulos MA, Pavlakis GN. Anti-SARS-CoV-2 Antibody Responses in Convalescent Plasma Donors Are Increased in Hospitalized Patients; Subanalyses of a Phase 2 Clinical Study. *Microorganisms*. 2020 Nov 28;8(12):1885. doi: 10.3390/microorganisms8121885. PMID: 33260775
 13. Bergamaschi, C., Pandit H., Nagy, B., **Stellas, D.**, Jensen, S., Bear, J., Cam, M., Valentin, A., Fox, B., Felber BK., Pavlakis, GN. Heterodimeric IL-15 delays tumor growth and promotes intratumoral CTL and dendritic cell accumulation by a cytokine network involving XCL1, IFN- γ , CXCL9 and CXCL10. *J Immunother Cancer*. 2020 May;8(1):e000599. doi: 10.1136/jitc-2020-000599.
 14. Salvanou, EA., **Stellas, D.**, Tsoukalas, C., Mavroidi. B., Paravatou-Petsotas, M., Kalogeropoulos, N., Xanthopoulos, S., Denat, F., Laurent, G., Bazzi, R., Roux, S., Bouziotis, P. A Proof-of-Concept Study on the Therapeutic Potential of Au Nanoparticles Radiolabeled with the Alpha-Emitter Actinium-225. *Pharmaceutics*. 2020 Feb 21;12(2). pii: E188. doi: 10.3390/pharmaceutics12020188.
 15. Karanika E, Soupsana K, Christogianni A, **Stellas D**, Klinakis A, Politou AS, Georgatos S.: Haspin-dependent and independent effects of the kinase inhibitor 5-Iodotubercidin on self-renewal and differentiation. *Sci Rep*. Jan 14;10(1):232. 2020
 16. Mameishvili E, Serafimidis I, Iwaszkiewicz S, Lesche M, Reinhardt S, Bölicke N, Büttner M, **Stellas D**, Papadimitropoulou A, Szabolcs M, Anastassiadis K, Dahl A, Theis F, Efstratiadis A, Gavalas A.: Aldh1b1 expression defines progenitor cells in the adult pancreas and is required for Kras-induced pancreatic cancer. *Proc Natl Acad Sci U S A*. Oct 8;116(41):20679-20688. 2019
 17. Pippa N, Stangel C, Kastanas I, Triantafyllopoulou E, Naziris N, **Stellas, D.**, Zhang M, Yudasaka M, Demetzos C, Tagmatarchis N.: Carbon nanohorn/liposome systems: Preformulation, design and in vitro toxicity studies. *Mater Sci Eng C Mater Biol Appl*. Dec; 105:110114. 2019
 18. Pippa, N., Naziris, N., **Stellas, D.**, Massala, C., Zouliati, K., Pispas, S., Demetzos, C., Forys, A., Marcinkowski, A., Trzebicka, B.: PEO-b-PCL grafted niosomes: the cooperativity of amphiphilic components and their properties in vitro and in vivo. *Colloids and Surfaces B: Biointerfaces* May (177):338-345. 2019
 19. Naziris, N., Pippa, N., **Stellas, D.**, Chrysostomou V., Libera, M., Trzebicka, B., Pispas, S., and Demetzos, C.: Development and Evaluation of Stimuli-responsive Chimeric Nanostructures. *AAPS PharmSciTech*. Oct;19(7):2971-2989. 2018
 20. Watson, D.C., Yung, B.C., Bergamaschi, C., Chowdhury, B., Bear, J., **Stellas, D.**, Morales-Kastresana, A., Jones, J.C., Felber, B.K., Chen, X., and Pavlakis, G.N.: Scalable, cGMP-compatible purification of extracellular vesicles carrying bioactive

- human heterodimeric IL-15 / Lactadherin complexes. *J Extracell Vesicles*. 28;7(1):1442088. 2018
21. Billiard, F., Karaliota, S., Wang, B., **Stellas**, D., Serafimidis, I., Manousopoulou, A., Koutmani, Y., Ninou, E., Golubov, J., DaNave, A., Tsakanikas, P., Xin, Y., Zhang, W., Sleeman, M., Yancopoulos, G.D., Murphy, A.J., Garbis, S.D., Karalis, K., and Skokos, D.: Delta-like ligand-4-notch signaling inhibition regulates pancreatic islet function and insulin secretion. *Cell Rep*. 22: 895-904. 2018.
 22. Matak, A., Lahiri, P., Ford, E., Pabst, D., Kashofer, K., **Stellas**, D., Thanos, D., and Zatloukal, K.: Stochastic phenotype switching leads to intratumor heterogeneity in human liver cancer. *Hepatology* 68(3):933-948. 2018
 23. Bouziotis, P., **Stellas**, D., Thomas, E., Truillet, C., Tsoukalas, C., Lux, F., Tsoதாக, T., Xanthopoulos, S., Paravatou-Petsotas, M., Gaitanis, A., Mouloupoulos, L.A., Koutoulidis, V., Anagnostopoulos, C.D., and Tillement, O. : 68Ga-radiolabeled AGuIX nanoparticles as dual-modality imaging agents for PET/MRI-guided radiation therapy. *Nanomedicine* (Lond) Dec 12: 1561-1574. 2017.
 24. Pippa, N., Chronopoulos, D.D., **Stellas**, D., Fernandez-Pacheco, R., Arenal, R., Demetzos, C., and Tagmatarchis, N.: Design and development of multi-walled carbon nanotube-liposome drug delivery platforms. *Int. J. Pharm.* July 7: 528: 429-439. 2017.
 25. Kouroupi, G., Taoufik, E., Vlachos, I.S., Tsioras, K., Antoniou, N., Papastefanaki, F., Chroni-Tzartou, D., Wrasidlo, W., Bohl, D., **Stellas**, D., Politis, P.K., Vekrellis, K., Vekrellis, K., Papadimitriou, D., Stefanis, L., Bregestovski, P., Hatzigeorgiou, A.G., Masliah, E., and Matsas, R.: Defective synaptic connectivity and axonal neuropathology in a human iPSC-based model of familial Parkinson's disease. *Proc. Natl. Acad. Sci. USA* 114: E3679-E3688. 2017.
 26. Pippa, N., **Stellas**, D., Skandalis, A., Pispas, S., Demetzos, C., Libera, M., Marcinkowski, A., and Trzebicka, B.: Chimeric lipid/block copolymer nanovesicles: physico-chemical and bio-compatibility evaluation. *Eur. J. Pharm. Biopharm.* 107: 295-309. 2016.
 27. Stivarou*, T., **Stellas***, D., Vartzi, G., Thomaidou, D., and Patsavoudi, E.: Targeting highly expressed extracellular HSP90 in breast cancer stem cells inhibits tumor growth in vitro and in vivo. *Cancer Biol. Ther.*17: 799-812. 2016. *equal contribution
 28. Kyrkou, A., **Stellas**, D., Syrrou, M., Klinakis, A., Fotsis, T., and Murphy, C.: Generation of human induced pluripotent stem cells in defined, feeder-free conditions. *Stem Cell Res*. 17: 458-460. 2016.
 29. Galani, A., Tsitsias, V., **Stellas**, D., Psycharis, V., Raptopoulou, C., and Karaliota, A.: Two novel compounds of vanadium and molybdenum with carnitine exhibiting potential pharmacological use. *J. Inorg. Biochem.* 142: 109-117. 2015.
 30. Karali, E., Bellou, S., **Stellas**, D., Klinakis, A., Murphy, C., and Fotsis, T.: VEGF signaling, mTOR complexes, and the endoplasmic reticulum: towards a role of metabolic sensing in the regulation of angiogenesis. *Mol. Cell Oncol.* 1: e964024. 2014.
 31. Truillet, C., Bouziotis, P., Brugiere, J., Martini, M., Sancey, L., Lux, F., Denat, F., Boschetti, F., **Stellas**, D., Anagnostopoulos, C., Koutoulidis, V., Mouloupoulos, L., Perriat, P., and Tillement, O.: Ultrasmall particles fo Gd-MRI and 68Ga-PET dual imaging. *Contrast Media Mol. Imaging* 10: 309-319. 2014.

32. **Stellas**, D., Szabolcs, M., Koul, S., Li, Z., Polyzos, A., Anagnostopoulos, C., Cournia, Z., Tamvakopoulos, C., Klinakis, A., and Efstratiadis, A.: Therapeutic effects of an anti-myc drug on mouse pancreatic cancer. *J. Natl. Cancer Inst.* 2014.
33. **Stellas**[#], D., Souliotis, V., Bekyrou, M., Smirlis, D., Kirsch-Volders, M., Cundari, E., and Kyrtopoulos, S.: Benzo[a]pyrene-induced cell cycle arrest in HepG2 cells is associated with delayed induction of mitotic instability. *Mutat. Res.* 769: 59-68. 2014. *corresponding author
34. Truillet, C., Bouziotis, P., Tsoukalas, C., Sancey, L., Denat, F., Boschetti, F., **Stellas**, D., Anagnostopoulos, C.D., Koutoulidis, V., Mouloupoulos, L.A., Lux, F., Perriat, P., and Tellement, O.: Innovative multimodal DOTA/NODA nanoparticles for MRI and PET imaging for tumor detection. *EJNMMI Phys.*, 1: A80. 2014.
35. Karali, E., Bellou, S., **Stellas**, D., Klinakis, A., Murphy, C., and Fotsis, T.: VEGF signals through ATF6 and PERK to promote endothelial cell survival and angiogenesis in the absence of ER stress. *Mol. Cell* 54: 559-572. 2014.
36. Foskolou, I.P., **Stellas**, D., Rozani, I., Lavigne, M.D., and Politis, P.K.: Prox1 suppresses the proliferation of neuroblastoma cells via a dual action in p27-Kip1 and Cdc25A. *Oncogene* 32: 947-960. 2013.
37. **Stellas**, D. and Patsavoudi, E.: Inhibiting matrix metalloproteinases., an old story with new potentials for cancer treatment. *Anticancer Agents Med Chem.* 9: 707-717, 2012.
38. **Stellas**, D., El Hamidieh, A., and Patsavoudi, E.: Monoclonal antibody 4C5 prevents activation of MMP2 and MMP9 by disrupting their interaction with extracellular HSP90 and inhibits formation of metastatic breast cancer cell deposits. *BMC Cell Biol.* 11: 51. 2010.
39. Sidera, K. Gaitanou, M., **Stellas**, D., Gaitanou, M., Matsas, R., and Patsavoudi, E.: A critical role for HSP90 in cancer cell invasion involves interaction with the extracellular domain of HER-2. *J. Biol. Chem.* 283: 2031-2041. 2008.
40. **Stellas**, D., Karameris, A., and Patsavoudi, E.: Monoclonal antibody 4C5 immunostains human melanomas and inhibits melanoma cell invasion and metastasis. *Clin. Cancer Res.* 13: 1831-1838. 2007.

: co-corresponding author, *: equal contribution

h-index: 22 (google scholar) Citations: 1402

Meeting Abstracts

1. **Stellas**, D., Villaras, G., Tsiambas, E., Karameris, A., and Patsavoudi, E.: Detection of Heat Shock Protein HSP90 in brain tumors with a new monoclonal antibody, mAb4C5. European Cancer Conference13, Paris, France, October 30-November 3, 2005.
2. **Stellas**, D. and Patsavoudi, E.: Aiming the upgrade of an in vitro laboratory. International Conference on Engineering Education, Athens, Greece, July 8-10, 2005.
3. **Stellas**, D. and Patsavoudi, E.: Inhibition of melanoma cell invasion in vitro with mAb 4C5, a new monoclonal antibody against heat shock protein 90. 57th Meeting of the Hellenic Society of Biochemistry and Molecular Biology, Athens, Greece, December 9-11, 2005.
4. **Stellas**, D. and Patsavoudi, E.: The monoclonal antibody, mAb 4C5 inhibits B16F10 melanoma cell invasion and metastasis in C57BL/6 mice. 3d Hellenic Anti Carcinogenic Congress, Athens, Greece, April 26-29, 2007.

5. **Stellas, D.** and Patsavoudi, E.: The monoclonal antibody, mAb 4C5 inhibits B16F10 melanoma cell invasion and metastasis. International Conference on Cancer Risk Assessment 2, Thira, Greece, May 25-27, 2007.
6. **Stellas, D.**, and Patsavoudi, E.: Extracellular HSP90 interacts with MMP2 and MMP9 and contributes to MDAMB453 human breast cancer cell metastasis in vivo. 33rd FEBS Congress, Athens, Greece, June 28-July 3, 2008.
7. **Stellas, D.**, Souliotis, V., Bekyrou, M., and Kyrtopoulos, S.: Discovering the molecular components of the B[a]P-induced S- phase arrest. European Environmental Mutagen Society, Cavtat, Croatia, September 21-25, 2008.
8. **Stellas, D.**, Souliotis, V.L., Bekyrou, M., Smirlis, D., Kirsch-Volders, M., Cundari, E., and Kyrtopoulos, S.A.: B[a]P Induced S-phase arrest: a double-edged sword. High-Throughput Screens in Genome Integrity and Cancer, Oxford, United Kingdom, May 24-27, 2010.
9. Karali, E., Bellou, S., **Stellas, D.**, Klinakis, A., Murphy, C., and Fotsis, T.: VEGF signals through ATF6 and PERK to promote endothelial cell survival and angiogenesis in the absence of ER stress. 64th HSBMB Congress, Athens, Greece, December 6-8, 2013.
10. Kouroupi, G., Taoufik, E., Tsioras, K., Bohl, D., Polyzos, A.P., Politis, P.K., **Stellas, D.**, Xilouri, M., Prodromidou, K., Antoniou, N., Chroni, D., Vekrellis, K., Bregestovski, P., Stefanis, L., Matsas, R.: iPS-derived neural cells from patients with familial Parkinson's disease carrying the A53T α -synuclein mutation. 26th Meeting of the Hellenic Neuroscience Society jointly with FP7 REGPOT Neurosign: Understanding Brain Function to Treat Dysfunction, Athens, Greece, November 29-December 1, 2013.
11. Kouroupi, G., Taoufik, E., Tsioras, K., Bohl, D., Polyzos, A.P., Politis, P.K., **Stellas, D.**, Prodromidou, K., Antoniou, N., Chroni, D., Vekrellis, K., Bregestovski, P., Stefanis, L., and Matsas, R.: iPS-derived neural cells from patients with familial Parkinson's disease carrying the A53T α -synuclein mutation. 43rd Annual Meeting of the Society for Neuroscience, San Diego, California, November 9-13, 2013.
12. Kouroupi, G., Taoufik, E., Tsioras, K., Bohl, D., Antoniou, N., Chroni, D., Politis, P., **Stellas, D.**, Vekrellis, K., Bregestovski, P., Stefanis, L., and Matsas, R.: Cellular stress responses of A53T alpha-synuclein iPS-derived neurons reveal defects in oxidative state, apoptosis and protein degradation. 12th Annual Meeting of the International Society for Stem Cell Research, Vancouver, Canada, June 28-21, 2014.
13. **Stellas, D.**, Szabolcs, M., Koul, S., Li, Z., Polyzos, A., Anagnostopoulos, C., Cournia, Z., Tamvakopoulos, C., Klinakis, A., and Efstratiadis, A.: Therapeutic effects of an anti-Myc drug on mouse pancreatic cancer. MYC: From Biology to Therapy, La Jolla, California, January 7 - 10, 2015.
14. **Stellas, D.**, Szabolcs, M., Koul, S., Li, Z., Polyzos, A., Anagnostopoulos, C., Cournia, Z., Tamvakopoulos, C., Klinakis, A., and Efstratiadis, A.: A small molecule Myc inhibitor has therapeutic effects on mouse pancreatic and other cancers. American Association for Cancer Research Annual Meeting, Philadelphia, Pennsylvania, April 18-22, 2015.
15. Kyrkou, A., Kouroupis, D., Triantafyllidi, E., Katsiboulas, M., **Stellas, D.**, Chalepakis, G., Syrrou, M., Klinakis, A., Georgoulis, A., Murphy, C., and Fotsis, T.: Differentiation of human induced pluripotent and mesenchymal stem cells on a 3D scaffold for anterior cruciate ligament regeneration. FEBS, Athens, Greece, October 11-14, 2014.

16. Karanika, E., Soupsana, K., Christogianni, A., **Stellas, D.**, Klinakis, A., Politou, A.S. and Georgatos, S.: KLF4 is overexpressed after treatment with 5-ITu, an inhibitor of Haspin, in mouse embryonic stem cells. FEBS, Athens, Greece, October 11-14, 2014.
17. Tsoutsis, L., Stratikopoulos, I., Klinakis, A., and **Stellas, D.**: Study of the expression of insulin growth factor I and II (IGFI and IGFII) during the development of mouse embryos. 66th Meeting of the Hellenic Society of Biochemistry and Molecular Biology, Athens, Greece, December 9-11, 2015.
18. Giannios, I., Soupsana, K., Chatzantonaki, E., Karakaidos, P., **Stellas, D.**, Klinakis, A., Politou, A.S., and Georgatos, S.: Increased dosage of LBR limits the dynamic range of Nanog fluctuations and downregulates Zscan4 in mouse embryonic stem cells. 67th Meeting of the Hellenic Society of Biochemistry and Molecular Biology. Ioannina, Greece, November 25-27, 2016
19. Markou, M., Kouroupis, D., **Stellas, D.**, Murphy, C., Fotsis, T., and Bagli, E.: Generation of mural cells from human pluripotent stem cells. 67th Meeting of the Hellenic Society of Biochemistry and Molecular Biology, Ioannina, Greece, November 25-27, 2016.
20. Morianos, I., Semitekolou, M., **Stellas, D.**, and Xanthou, G.: Activin-A potentiates anti-tumor immunity and protects against lung cancer progression in vivo. International Congress of Immunology, Melbourne, Australia, August 21-26, 2016.
21. Bergamaschi, C., Dimas, K., **Stellas D.**, Nagy, B., Jensen, S.M., Fox, B.A., Felber, B.K., and Pavlakis, G.N.: Treatment with heterodimeric IL-15 promotes effector T cell infiltration into several tumor types. 5th Annual Meeting of the International Cytokine and Interferon Society, Kanazawa, Japan, October 29-November 2, 2017.
22. Bergamaschi, C., Dimas, K., **Stellas D.**, Nagy, B., Jensen, S.M., Fox, B.A., Felber, B.K., and Pavlakis, G.N.: Treatment with heterodimeric IL-15 promotes effector T cell infiltration into tumors. The Society of Immunotherapy of Cancer (SITC) 32nd Annual Meeting, National Harbor, Maryland, November 8-12, 2017
23. **Stellas, D.**, Dimas, K., Nagy, B.A., Valentin, A., Felber, B.K., and Pavlakis, G.N.: Heterodimeric interleukin 15 (hetIL-15) treatment decreases primary breast cancer 4T1 tumors and alleviates the metastatic burden. Association for Cancer Research Annual Meeting, Chicago, Illinois, April 14-18, 2018.
24. Vidali, V., Cournia, Z., Papadimitropoulou, A., **Stellas, D.**, Klinakis, A., Couladouros, E., Tamvakopoulos, C. and Efstratiadis, A.: Design, synthesis, and efficacy of MYC inhibitors in mouse pancreatic cancer. Association for Cancer Research Annual Meeting, Chicago, Illinois, April 14-18, 2018.
25. Bergamaschi, C., Nagy, B., Jensen, S.M., Dimas, K., **Stellas, D.**, Fox, B.A., Pavlakis, G.N., and Felber, B.K.: Treatment with heterodimeric IL-15 promotes effector T cell infiltration into tumors: a general method for lymphocyte entry in tumors. 14th Annual CCR and DCEG Staff Scientist and Staff Clinician Retreat, Rockville, Maryland, April 6, 2018.
26. Watson, D.C., Yung, B.C., Bayik, D., Srivatsan, A., Bergamaschi, C., **Stellas, D.**, Felber, B.K., Chen, X., and Pavlakis, G.N.: Engineered extracellular vesicles carrying heterodimeric IL-15: production, characterization and tumor delivery. American Society of Gene and Cell Therapy Annual Meeting, Chicago, Illinois, May 16-19, 2018.
27. Bergamaschi, C., Nagy, B.A., Jensen S.M., Dimas, K., **Stellas, D.**, Fox B.A., Felber, B.K., and Pavlakis, G.N.: Treatment with heterodimeric IL-15 shapes the cytokine milieu of the tumor promoting tumor infiltration by cytotoxic

- lymphocytes: A general method for lymphocyte entry in tumors. Cytokines Annual Meeting, Boston, October 27-30, 2018.
28. **Bergamaschi C., Stellas D.**, Karaliota S., Nagy B.A., Jensen S. M., Fox B., Dimas K., Felber B.K., and Pavlakis G.N. Heterodimeric IL-15 shapes the tumor cytokine and chemokine milieu, promoting myeloid-lymphoid cells interactions and immune cell recruitments into the tumors. *Cytokines 2019*, 20-23 October 2019, Vienna, Austria.
 29. **Stellas, D.**, Stravokefalou, V., Karaliota, S., Kalen, J., Dimas, K., Kozlov, S., Felber, B.K., and Pavlakis, G.N.: Dose sparing effect and prolonged survival effect of heterodimeric interleukin-15 (IL-15) in combination with gemcitabine in KPC GEM model of pancreatic cancer. 15th Annual NIH Graduate Student Research Symposium, Bethesda, Maryland, February 21, 2019
 30. **Stellas, D.**, Karaliota, S., Stravokefalou, V., Nagy, B.A., Felber, B.K., and Pavlakis, G.N.: Heterodimeric IL-15 monotherapy results in complete regression of EO771 murine breast tumors through cDC1-lymphocyte interactions and induction of antitumor immunity. American Association for Cancer Research Annual Meeting, Atlanta, Georgia, March 29-April 3, 2019.
 31. Bergamaschi, C., Stellas, D., Karaliota, S., Nagy, B.A., Jensen S.M., Fox, B., Dimas, K., **Stellas, D.**, Felber, B.K., and Pavlakis, G.N.: Heterodimeric IL-15 shapes the tumor cytokine and chemokine milieu, promoting myeloid-lymphoid cells interactions and immune cell recruitments into the tumors. Cytokines 2019, Vienna, Austria, October 20-23, 2019.
 32. **Stellas, D.**, Stravokefalou, V., Karaliota, S., Nagy, B., Guerin, T., Kozlov, S., Dimas, K., Felber, B.K., and Pavlakis, G.N.: Combination of hetIL-15 with chemotherapy in triple negative breast and pancreatic cancer mouse models increases tumor necrosis and alleviates metastatic disease. 20th Annual CCR-FYI Colloquium, Rockville, March 12-13, 2020.
 33. Karaliota S., **Stellas, D.**, Stravokefalou, V., Nagy, B., Bergamaschi, C., Felber, B.K., and Pavlakis, G.N.: Complete regression of murine breast tumors by hetIL-15FC monotherapy correlates with infiltration by T, NK, cDC1 cells and a novel population of dendritic cells. 20th Annual CCR-FYI Colloquium, Rockville, March 12-13, 2020.
 34. Pavlakis, G.N., Bergamaschi, C., **Stellas, D.**, Karaliota, S., Nagy, B., Stravokefalou, V., Dimas, K., Jensen, S.M., Fox, B.A., and Felber, B.K.: Mechanism of Heterodimeric IL-15 in tumor reduction: Induction of myeloid-lymphoid cell interactions leads to IFN- γ dependent lymphocyte recruitment by dendritic cells into tumors. IMMUNOLOGY2020. Honolulu, Hawaii, May 8-12, 2020.
 35. Pavlakis, G.N., Karaliota, S., **Stellas, D.**, Bergamaschi, C., Stravokefalou, V., Nagy, B., and Felber, B.K.: Regression of murine breast tumors after hetIL-15 monotherapy correlates with a novel population of intratumoral dendritic cells, in addition to increased infiltration of T, NK and cDC1 cells. IMMUNOLOGY2020. Honolulu, Hawaii, May 8-12, 2020
 36. Karaliota, S., **Stellas, D.**, Stravokefalou, V., Nagy, B., Bergamaschi, C., Felber, B.K., and Pavlakis, G.N.: Complete regression of murine breast tumors by hetIL-15FC monotherapy correlates with infiltration by T, NK, cDC1 cells and a novel population of dendritic cells. AACR Annual Meeting 2020, Virtual Meeting II, June 22-24, 2020. (*Invited oral*)
 37. **Stellas, D.**, Stravokefalou, V., Karaliota, S., Nagy, B., Kozlov, S., Dimas, K., Felber, B.K., and Pavlakis, G.N.: Combination of hetIL-15 with chemotherapy in

- triple negative breast and pancreatic cancer mouse models increases tumor necrosis and alleviates metastatic disease. AACR Annual Meeting 2020, Virtual Meeting II, June 22-24, 2020.
38. **Stellas D.**, Karaliota S., Stravokefalou V., Nagy B.A., Cristina Bergamaschi C., Felber B.K. and Pavlakis, G.N. Complete regression of murine breast tumors and long-term anti-tumor immunity by hetIL-15 monotherapy is mediated through the interaction of T, NK, cDC1 cells and a novel population of dendritic cells. *Cytokines 2020*, 1-4 November, Virtual Meeting (*Milstein Abstract Award*).
 39. Bergamaschi C, Pandit H, Nagy B, **Stellas D.**, Karaliota, S Jensen, S. M., Dimas K., Fox B.A, Felber B.F, Pavlakis G.N. Heterodimeric IL-15 therapy promotes intratumoral lymphocytes and dendritic cell accumulation by a cytokine network involving XCL1, INF-gamma, CXCL9 and CXCL10, resulting in control of primary and metastatic tumor. 8th annual meeting of the cytokines and interferon society, 1-4 November 2020.
 40. Karaliota S., **Stellas D.**, Stravokefalou V., Nagy B.A., Felber B.K. and Pavlakis, G.N. hetIL-15 monotherapy increases intratumoral CD8⁺ T cytotoxic cells and reverses the metabolic dysfunction in murine breast tumors. *Keystone Symposia 2020*, 25-28 January, Virtual meeting.
 41. **Stellas D.**, Stravokefalou V., Karaliota S., Nagy B., Bergamaschi C., Felber B.K and Pavlakis G.N. A Novel Dendritic Cell Population Infiltrates Murine Breast Cancer Tumors along with Conventional Dendritic Cells, Enhancing the Immune Response after Heterodimeric IL-15 (hetIL-15) Monotherapy. 21st Annual Center for Cancer Research Fellows and Young Investigators (CCR-FYI) Colloquium. From Mechanisms to Therapies: Current Highlights in Cancer Research. April 19th- 20th, 2021